Ten of the world’s largest pharmaceutical companies said on Wednesday that they would cooperate on research aimed at accelerating drug development, starting with streamlining clinical trials.
Pharmaceutical companies have collaborated before on areas considered not directly competitive, such as finding variants in the human genome and biomarkers to predict disease and the effectiveness of drugs. But the people behind the new effort said it would be the largest of its kind.
Read the full story: http://nyti.ms/UjLqhc
Source: The New York Times
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More